<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944957</url>
  </required_header>
  <id_info>
    <org_study_id>IEC 09-087</org_study_id>
    <nct_id>NCT00944957</nct_id>
  </id_info>
  <brief_title>Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz</brief_title>
  <acronym>Switch-ER</acronym>
  <official_title>Patient Preference, Sleep Quality, and Anxiety/Depression: Comparison of Raltegravir and Efavirenz</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Lugano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Neuchâtel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efavirenz causes neuropsychiatric side effects and sleep disturbance, including vivid dreams,
      dizziness, and abnormal tiredness. These symptoms are frequent during the first weeks of
      treatment, with subsequent attenuation but may not completely resolve even years after
      efavirenz initiation.

      The investigators plan a four week, randomized, placebo-controlled, double-blind study. In
      group 1, efavirenz will be replaced with efavirenz placebo plus raltegravir, in group 2,
      efavirenz would be continued, and raltegravir placebo given in addition. After two weeks,
      patients in group 1 would switch to the regimen of group 2, and vice versa.

      The primary endpoint of the trial will be patient preference. Sleep quality, daytime
      sleepiness, and anxiety will also be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms and neurological side effects of study drugs</measure>
    <time_frame>baseline, week 2 and week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of daytime sleepiness</measure>
    <time_frame>baseline, week 2 and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>baseline, week 2 and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression, anxiety and stress will be assessed</measure>
    <time_frame>baseline, week 2 and week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sleep Disorders</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Raltegravir for first 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Efavirenz for first 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir for the first 2 weeks</intervention_name>
    <description>Patient receives raltegravir and efavirenz placebo during the first 2 weeks</description>
    <arm_group_label>Raltegravir first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz for the last 2 weeks</intervention_name>
    <description>Patient receives efavirenz and raltegravir placebo during the last 2 weeks</description>
    <arm_group_label>Raltegravir first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz for the first 2 weeks</intervention_name>
    <description>Efavirenz and raltegravir placebo for the first 2 weeks</description>
    <arm_group_label>Efavirenz first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir for the last 2 weeks</intervention_name>
    <description>Raltegravir and efavirenz placebo for the last 2 weeks</description>
    <arm_group_label>Efavirenz first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt; 18 years

          -  Signing the study consent form and agree to change ART regimen

          -  Stable HAART including EFV since at least 3 months

          -  HIV-RNA below 50 copies for at least 3 months

        Exclusion Criteria:

          -  No major psychiatric disease (psychosis, severe depression) diagnosed before the
             initiation of EFV

          -  Mentally incompetent patients

          -  Pregnancy or lactation Women of childbearing potential must use one or two reliable
             contraceptive methods during the trial, from day 1 to the end of week 12. Acceptable
             methods include the birth control pill, IUD, condoms with spermicides. Non-acceptable
             methods include (non-exhaustive list): Withdrawal, calendar (Onigo method), or
             spermicides alone.

          -  Concomitant renal or hepatic disease:

               -  Creatinine above 150 micromol/L

               -  Transaminases above 5 times upper normal limit

               -  Prothrombin (Quick) value below 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard BH Hirschel, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geneva Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernard BH Hirschel, Professor</last_name>
    <phone>022 372 98 11</phone>
    <phone_ext>+41</phone_ext>
    <email>bernard.hirschel@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hopistal of Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard BH Hirschel, Professor</last_name>
      <phone>022 372 98 11</phone>
      <phone_ext>+41</phone_ext>
      <email>bernard.hirschel@hcuge.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.shcs.ch</url>
    <description>Swiss HIV Cohort Study</description>
  </link>
  <link>
    <url>http://www.doctorswiss.ch/bernard-hirschel/</url>
    <description>Homepage Bernard Hirschel</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>January 11, 2010</last_update_submitted>
  <last_update_submitted_qc>January 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professeur Bernard Hirschel</name_title>
    <organization>Geneva infectious diseases</organization>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>efavirenz</keyword>
  <keyword>anxiety</keyword>
  <keyword>depression</keyword>
  <keyword>sleep quality</keyword>
  <keyword>HIV</keyword>
  <keyword>NNRTI</keyword>
  <keyword>Tritherapy</keyword>
  <keyword>compliance</keyword>
  <keyword>stocrin</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 9, 2011</submitted>
    <returned>September 12, 2011</returned>
    <submitted>September 15, 2011</submitted>
    <returned>October 24, 2011</returned>
    <submitted>October 25, 2011</submitted>
    <returned>November 28, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

